View ValuationEnhanced Group 将来の成長Future 基準チェック /26Enhanced Groupは、84.9%と85%でそれぞれ年率84.9%で利益と収益が成長すると予測される一方、EPSはgrowで80.5%年率。主要情報84.9%収益成長率80.52%EPS成長率Specialty Retail 収益成長9.1%収益成長率85.0%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日14 Aug 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Aug 19Enhanced Group Announces Enhanced OS The AI Powered Operating System For Delivering Human PotentialEnhanced Group announced Enhanced OS, an artificial intelligence-powered platform designed to become the operating system for human potential. Enhanced OS is scheduled to launch during 2026, with additional features, access, and full commercial details to be shared in the coming months. Enhanced OS will provide the same tools once reserved for elite athletes: a personalized plan, protocol, doctor, game, and coach all powered by AI with the highest levels of medical supervision and access to regulated prescription therapy products. Enhanced OS is designed to learn who a member is, what they're trying to achieve, and where they're starting from. It then builds a personalized path forward that regularly changes and optimizes using insights drawn from Enhanced’s elite athletic performance team. Enhanced OS is designed to: Learn continuously from a customer’s medical records, biomarkers, and wearable data to refine each member's plan over time; Combine AI and clinical expertise, AI drafts, monitors, and recommends, while licensed doctors take the baton and retain all clinical decision-making. Each of the data points generated through the clinical trial will be training data, to help make this the best personalization platform in the market; Pair every plan with human accountability, encouraging members to test their progress and development in community-led participation events such as run-clubs; Bridge the digital and physical, offering the ability to link each member's health journey to a community, competition, or live events they themselves select because transformation won’t happen entirely on a screen. The Company plans to offer a tier of the OS system that will remain free indefinitely, serving as the front door to the Enhanced ecosystem and giving members a reason to get educated and gain greater trust before any purchase is made. From there, enhancement will exist on a spectrum. For some, that means personalized supplementation, training, and nutrition anchored to a real event like a marathon or competition. For others, the spectrum may include a full clinical protocol built around individual biomarkers and goals. Enhanced OS is built to deliver across this spectrum of human optimization at any level a consumer wants. Enhanced intends to keep its customers throughout their health journey, by adapting as their goals, circumstances, and physiology evolve, rather than treating health as a one-time transaction. Members who experience real results create advocacy no advertising budget can buy.お知らせ • Aug 07Enhanced Group Inc. to Report Q2, 2026 Results on Aug 13, 2026Enhanced Group Inc. announced that they will report Q2, 2026 results After-Market on Aug 13, 2026お知らせ • Jun 30Enhanced Launches the Thor Protocol Product Stack on Its Live Enhanced PlatformEnhanced had announced the launch of its Thor Protocol, a comprehensive, clinician-supervised performance product stack available exclusively through its Live Enhanced consumer platform. The Thor Protocol is designed to help consumers support their strength, recovery, and physical performance under the guidance of licensed clinicians. The stack reflects the same evidence-based, medically supervised philosophy that has defined Enhanced's approach to elite athlete performance. Thor’s Protocol includes three clinician-prescribed products, each personalized to the individual’s lab results and health profile. Testosterone levels decline with age. Published research shows that clinician-supervised testosterone therapy helps support lean body composition, energy, and vitality in men that qualify. Long-term data show favorable effects on body composition, mood, and metabolic markers when levels are maintained within the physiological range. Thor’s protocol starts with baseline bloodwork, with dosing matched to individual needs and monitored over time. NAD+ is a coenzyme central to cellular energy metabolism. Levels decline naturally with age, and research suggests that supporting NAD+ levels helps support cellular energy production and healthy aging. A 2025 study in Nature detailed NAD+’s role in mitochondrial function and cellular resilience, and preclinical research has shown that restoring NAD+ levels supports energy production and supports markers associated with healthy aging. The Enhanced NAD+ protocol is clinician-supervised, with dosage matched to the individual. Daily low-dose tadalafil supports healthy blood flow by promoting nitric oxide-mediated vasodilation. Clinical research supports improvements in endothelial function and vascular tone, with trials reporting better circulation and improved endothelial function. The protocol is clinician-supervised with daily dosing personalized to the individual. For strength athletes, the problem isn’t one system slowing down. It’s multiple systems declining at the same time: hormonal output, cellular energy, vascular function. Thor’s Protocol is intended to address these areas through individualized clinician-guided treatment. Testosterone supports the hormonal foundation. NAD+ supports cellular energy production and recovery at the mitochondrial level. Tadalafil supports blood flow and vascular function. Individually, each addresses a real gap. Together, the protocol addresses multiple physiological systems through individualized clinician-guided care. Every protocol starts with a clinician review by a licensed clinician through Enhanced’s healthcare provider partners. Every protocol is monitored over time, and adjusted as the individual’s data changes. This is not a one-size-fits-all stack off a shelf. It’s a clinician-guided protocol matched to the consumer's physiology. Thor's Protocol is available now exclusively through the Live Enhanced platform. Clinician-prescribed products require a consultation with a licensed provider through the platform.お知らせ • Jun 15Enhanced Group Inc. announced that it expects to receive $49.999991 million in funding from Apeiron Investment Group LimitedEnhanced Group Inc. announced that it has entered into an agreement to issue 12,853,468 shares of its Class A common stock (the "Common Stock") at a purchase price per share equal to $3.89 per share and 12,853,468 warrants to purchase Common Stock with an exercise price of $3.89 per share for the gross proceeds of $50 million. The initial tranche of the PIPE is expected to close on or about June 17, 2026 with the remaining two tranches in aggregate expected to close within forty-five days of the initial closing, in each case subject to satisfaction of customary closing conditions. The Private Placement is expected to close in three tranches, with approximately $25.0 million of the gross proceeds expected to close on or about June 17, 2026 (the “First Closing”), approximately $11.75 million of the gross proceeds expected to close on or about June 22, 2026 and the remaining approximately $13.25 million of the gross proceeds in third tranche. The transaction involves participation of Apeiron Investment Group Limited and Maximilian Martin, Chief Executive Officer of the Company and a member of the Board of Directors of the Company as an investors.Seeking Alpha • May 28Enhanced Group: A Bet On Peptide And PED Overton Window ShiftSummary Enhanced Group Inc. is a highly differentiated and ambitious telehealth company. The company offers peptides and supplemental health products to enhance performance. ENHA is trying to capture interest from a growing biohacking market, but the market's controversy and peptides' unreliable health results may weaken market potential. The Enhanced Games, a massive marketing funnel for ENHA, had a mixed inaugural event. Controversy boosted its audience, but only one world record was broken. At a $370 million market cap, the market is skeptical of ENHA's success. Read the full article on Seeking Alphaお知らせ • May 22Enhanced Group, Inc. Provides Clinical Trial Update for Enhanced Medical ProgramEnhanced, announced that its Institutional Review Board (IRB) approved clinical study has been posted for review to ClinicalTrials.gov. The study is part of the Enhanced Medical Program, which gives athletes the opportunity to consider FDA-approved substances, prescribed by doctors as part of the study, and continuous medical screenings to explore enhancements in the safest possible manner. The interventional phase of the trial has now concluded, with the five-year observational monitoring period now commencing. The trial can be located on ClinicalTrials.gov by typing the study acronym "ASCEND001" into the 'other terms' search bar on the homepage. Alternatively, viewers can enter the study's title "Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes" as a search cue. With the inaugural Enhanced Games fast approaching on Sunday May 24th (8:30pm EDT/5:30pm PDT) in Las Vegas, the company also announced preliminary details regarding approved substance usage by athletes during the 12-week trial period. The company will not be commenting further on these aggregate totals until the scheduled Enhanced Games press conference on Saturday May 23rd (1:15pm PST) before the approximately 200 credentialed media from 20 different countries who are expected in attendance. The clinical trial encompassed 36 of the 42 athletes competing. Of those 36 athletes, 2 are competing naturally. Six athletes did not participate in the study with two of those six competing naturally. Athletes participating in the study were permitted to consider substances across five approved categories, including testosterone esters, anabolic agents, peptides and growth factors, metabolic modulators, and stimulants. Only legal substances under U.S. Food & Drug Administration (FDA) guidelines were studied. No peptides currently on the FDA's Category 2 banned list were included in the research. With the interventional period now concluded, Enhanced is releasing aggregate information reflecting the substances incorporated into each athlete's personalized protocols. Individual athlete protocols will not be made publicly available by Enhanced. According to aggregate data collected in the lead up to the Games: 91% of athletes used testosterone or testosterone esters; 79% of athletes used human growth hormone (hGH); 62% of athletes used stimulants (eg. Adderall); 50% of athletes used metabolic modulators, primarily ancillary compounds (eg. Anastrozole) which was used alongside anabolic agents to support protocols; 41% of athletes used erythropoietin (EPO); 29% of athletes used an anabolic steroid agent (eg. Deca durabolin); 5% of athletes used hormonal support therapies (eg. hCG). The clinical data generated through this study is proprietary to Enhanced and forms the foundation of the company's competitive moat. No other consumer health platform in the world is designing personalized enhancement protocols informed by IRB-approved elite athlete research. Through the Live Enhanced platform, learnings from elite performance environments will flow directly into individualized consumer protocols, continuously improving product recommendations and personalizing the experience at scale. The primary objective of the study is to assess the safety and tolerability of certain approved medical compounds when administered to adult athletes under individualized medical supervision over a treatment period of up to 25 weeks. Primary endpoints include the incidence of treatment-related adverse events and the proportion of participants who discontinue use due to such events. Secondary objectives include evaluating changes in physiological and performance-related parameters through structured baseline and follow-up assessments. Assessments include cardiology evaluation and imaging, respiratory testing, organ health imaging, body composition analysis, musculoskeletal assessment, neurocognitive screening and biomarker analysis using blood, urine and saliva samples. All participants underwent comprehensive baseline assessments, ongoing medical monitoring during the treatment period, and will receive structured long-term follow-up for up to five years to assess health outcomes. All substances used in the study were approved by relevant health authorities and were procured through regulated pharmaceutical supply chains. Administration, dosages, adjustment, interruption, or discontinuation of any substance were determined by the Principal Investigators based on individualized medical evaluation and in accordance with IRB-approved protocols in collaboration with the independent medical and science commission. Participants participated with full consent and may decline or discontinue participation at any time. The study is sponsored by Enhanced. Clinical oversight and decision-making are the responsibility of the Principal Investigators and were subject to independent monitoring mechanisms, including a Data and Safety Monitoring Board.Board Change • May 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.業績と収益の成長予測NYSE:ENHA - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202825713129106312/31/2027132-252120312/31/202644-76-65-5426/30/202618-99-69-61N/A3/31/20260-40-43-40N/A12/31/2025N/A-27-25-24N/A9/30/2025N/A-14-13-13N/A12/31/2024N/A-5-3-3N/Aアナリストによる今後の成長予測収入対貯蓄率: ENHA今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: ENHA今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: ENHA今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: ENHAの収益 ( 85% ) US市場 ( 12.9% ) よりも速いペースで成長すると予測されています。高い収益成長: ENHAの収益 ( 85% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ENHAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YRetail 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/24 14:39終値2026/08/21 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Enhanced Group Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Matthew AbrahamBerenbergSusan AndersonCanaccord GenuityAlex FuhrmanLucid Capital Markets
お知らせ • Aug 19Enhanced Group Announces Enhanced OS The AI Powered Operating System For Delivering Human PotentialEnhanced Group announced Enhanced OS, an artificial intelligence-powered platform designed to become the operating system for human potential. Enhanced OS is scheduled to launch during 2026, with additional features, access, and full commercial details to be shared in the coming months. Enhanced OS will provide the same tools once reserved for elite athletes: a personalized plan, protocol, doctor, game, and coach all powered by AI with the highest levels of medical supervision and access to regulated prescription therapy products. Enhanced OS is designed to learn who a member is, what they're trying to achieve, and where they're starting from. It then builds a personalized path forward that regularly changes and optimizes using insights drawn from Enhanced’s elite athletic performance team. Enhanced OS is designed to: Learn continuously from a customer’s medical records, biomarkers, and wearable data to refine each member's plan over time; Combine AI and clinical expertise, AI drafts, monitors, and recommends, while licensed doctors take the baton and retain all clinical decision-making. Each of the data points generated through the clinical trial will be training data, to help make this the best personalization platform in the market; Pair every plan with human accountability, encouraging members to test their progress and development in community-led participation events such as run-clubs; Bridge the digital and physical, offering the ability to link each member's health journey to a community, competition, or live events they themselves select because transformation won’t happen entirely on a screen. The Company plans to offer a tier of the OS system that will remain free indefinitely, serving as the front door to the Enhanced ecosystem and giving members a reason to get educated and gain greater trust before any purchase is made. From there, enhancement will exist on a spectrum. For some, that means personalized supplementation, training, and nutrition anchored to a real event like a marathon or competition. For others, the spectrum may include a full clinical protocol built around individual biomarkers and goals. Enhanced OS is built to deliver across this spectrum of human optimization at any level a consumer wants. Enhanced intends to keep its customers throughout their health journey, by adapting as their goals, circumstances, and physiology evolve, rather than treating health as a one-time transaction. Members who experience real results create advocacy no advertising budget can buy.
お知らせ • Aug 07Enhanced Group Inc. to Report Q2, 2026 Results on Aug 13, 2026Enhanced Group Inc. announced that they will report Q2, 2026 results After-Market on Aug 13, 2026
お知らせ • Jun 30Enhanced Launches the Thor Protocol Product Stack on Its Live Enhanced PlatformEnhanced had announced the launch of its Thor Protocol, a comprehensive, clinician-supervised performance product stack available exclusively through its Live Enhanced consumer platform. The Thor Protocol is designed to help consumers support their strength, recovery, and physical performance under the guidance of licensed clinicians. The stack reflects the same evidence-based, medically supervised philosophy that has defined Enhanced's approach to elite athlete performance. Thor’s Protocol includes three clinician-prescribed products, each personalized to the individual’s lab results and health profile. Testosterone levels decline with age. Published research shows that clinician-supervised testosterone therapy helps support lean body composition, energy, and vitality in men that qualify. Long-term data show favorable effects on body composition, mood, and metabolic markers when levels are maintained within the physiological range. Thor’s protocol starts with baseline bloodwork, with dosing matched to individual needs and monitored over time. NAD+ is a coenzyme central to cellular energy metabolism. Levels decline naturally with age, and research suggests that supporting NAD+ levels helps support cellular energy production and healthy aging. A 2025 study in Nature detailed NAD+’s role in mitochondrial function and cellular resilience, and preclinical research has shown that restoring NAD+ levels supports energy production and supports markers associated with healthy aging. The Enhanced NAD+ protocol is clinician-supervised, with dosage matched to the individual. Daily low-dose tadalafil supports healthy blood flow by promoting nitric oxide-mediated vasodilation. Clinical research supports improvements in endothelial function and vascular tone, with trials reporting better circulation and improved endothelial function. The protocol is clinician-supervised with daily dosing personalized to the individual. For strength athletes, the problem isn’t one system slowing down. It’s multiple systems declining at the same time: hormonal output, cellular energy, vascular function. Thor’s Protocol is intended to address these areas through individualized clinician-guided treatment. Testosterone supports the hormonal foundation. NAD+ supports cellular energy production and recovery at the mitochondrial level. Tadalafil supports blood flow and vascular function. Individually, each addresses a real gap. Together, the protocol addresses multiple physiological systems through individualized clinician-guided care. Every protocol starts with a clinician review by a licensed clinician through Enhanced’s healthcare provider partners. Every protocol is monitored over time, and adjusted as the individual’s data changes. This is not a one-size-fits-all stack off a shelf. It’s a clinician-guided protocol matched to the consumer's physiology. Thor's Protocol is available now exclusively through the Live Enhanced platform. Clinician-prescribed products require a consultation with a licensed provider through the platform.
お知らせ • Jun 15Enhanced Group Inc. announced that it expects to receive $49.999991 million in funding from Apeiron Investment Group LimitedEnhanced Group Inc. announced that it has entered into an agreement to issue 12,853,468 shares of its Class A common stock (the "Common Stock") at a purchase price per share equal to $3.89 per share and 12,853,468 warrants to purchase Common Stock with an exercise price of $3.89 per share for the gross proceeds of $50 million. The initial tranche of the PIPE is expected to close on or about June 17, 2026 with the remaining two tranches in aggregate expected to close within forty-five days of the initial closing, in each case subject to satisfaction of customary closing conditions. The Private Placement is expected to close in three tranches, with approximately $25.0 million of the gross proceeds expected to close on or about June 17, 2026 (the “First Closing”), approximately $11.75 million of the gross proceeds expected to close on or about June 22, 2026 and the remaining approximately $13.25 million of the gross proceeds in third tranche. The transaction involves participation of Apeiron Investment Group Limited and Maximilian Martin, Chief Executive Officer of the Company and a member of the Board of Directors of the Company as an investors.
Seeking Alpha • May 28Enhanced Group: A Bet On Peptide And PED Overton Window ShiftSummary Enhanced Group Inc. is a highly differentiated and ambitious telehealth company. The company offers peptides and supplemental health products to enhance performance. ENHA is trying to capture interest from a growing biohacking market, but the market's controversy and peptides' unreliable health results may weaken market potential. The Enhanced Games, a massive marketing funnel for ENHA, had a mixed inaugural event. Controversy boosted its audience, but only one world record was broken. At a $370 million market cap, the market is skeptical of ENHA's success. Read the full article on Seeking Alpha
お知らせ • May 22Enhanced Group, Inc. Provides Clinical Trial Update for Enhanced Medical ProgramEnhanced, announced that its Institutional Review Board (IRB) approved clinical study has been posted for review to ClinicalTrials.gov. The study is part of the Enhanced Medical Program, which gives athletes the opportunity to consider FDA-approved substances, prescribed by doctors as part of the study, and continuous medical screenings to explore enhancements in the safest possible manner. The interventional phase of the trial has now concluded, with the five-year observational monitoring period now commencing. The trial can be located on ClinicalTrials.gov by typing the study acronym "ASCEND001" into the 'other terms' search bar on the homepage. Alternatively, viewers can enter the study's title "Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes" as a search cue. With the inaugural Enhanced Games fast approaching on Sunday May 24th (8:30pm EDT/5:30pm PDT) in Las Vegas, the company also announced preliminary details regarding approved substance usage by athletes during the 12-week trial period. The company will not be commenting further on these aggregate totals until the scheduled Enhanced Games press conference on Saturday May 23rd (1:15pm PST) before the approximately 200 credentialed media from 20 different countries who are expected in attendance. The clinical trial encompassed 36 of the 42 athletes competing. Of those 36 athletes, 2 are competing naturally. Six athletes did not participate in the study with two of those six competing naturally. Athletes participating in the study were permitted to consider substances across five approved categories, including testosterone esters, anabolic agents, peptides and growth factors, metabolic modulators, and stimulants. Only legal substances under U.S. Food & Drug Administration (FDA) guidelines were studied. No peptides currently on the FDA's Category 2 banned list were included in the research. With the interventional period now concluded, Enhanced is releasing aggregate information reflecting the substances incorporated into each athlete's personalized protocols. Individual athlete protocols will not be made publicly available by Enhanced. According to aggregate data collected in the lead up to the Games: 91% of athletes used testosterone or testosterone esters; 79% of athletes used human growth hormone (hGH); 62% of athletes used stimulants (eg. Adderall); 50% of athletes used metabolic modulators, primarily ancillary compounds (eg. Anastrozole) which was used alongside anabolic agents to support protocols; 41% of athletes used erythropoietin (EPO); 29% of athletes used an anabolic steroid agent (eg. Deca durabolin); 5% of athletes used hormonal support therapies (eg. hCG). The clinical data generated through this study is proprietary to Enhanced and forms the foundation of the company's competitive moat. No other consumer health platform in the world is designing personalized enhancement protocols informed by IRB-approved elite athlete research. Through the Live Enhanced platform, learnings from elite performance environments will flow directly into individualized consumer protocols, continuously improving product recommendations and personalizing the experience at scale. The primary objective of the study is to assess the safety and tolerability of certain approved medical compounds when administered to adult athletes under individualized medical supervision over a treatment period of up to 25 weeks. Primary endpoints include the incidence of treatment-related adverse events and the proportion of participants who discontinue use due to such events. Secondary objectives include evaluating changes in physiological and performance-related parameters through structured baseline and follow-up assessments. Assessments include cardiology evaluation and imaging, respiratory testing, organ health imaging, body composition analysis, musculoskeletal assessment, neurocognitive screening and biomarker analysis using blood, urine and saliva samples. All participants underwent comprehensive baseline assessments, ongoing medical monitoring during the treatment period, and will receive structured long-term follow-up for up to five years to assess health outcomes. All substances used in the study were approved by relevant health authorities and were procured through regulated pharmaceutical supply chains. Administration, dosages, adjustment, interruption, or discontinuation of any substance were determined by the Principal Investigators based on individualized medical evaluation and in accordance with IRB-approved protocols in collaboration with the independent medical and science commission. Participants participated with full consent and may decline or discontinue participation at any time. The study is sponsored by Enhanced. Clinical oversight and decision-making are the responsibility of the Principal Investigators and were subject to independent monitoring mechanisms, including a Data and Safety Monitoring Board.
Board Change • May 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.